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Background: The prevalence of central venous catheter (CVC)-related blood-stream infections (CRBSI),
infecting agents and the effectiveness of antibiotic therapy were evaluated in 172 adult patients on Home
Parenteral Nutrition (HPN) at the Clinical Nutrition Outpatient Unit of Federico II University Hospital in
Naples, Italy.
Materials and methods: The study population consisted of 127 oncological (74%) and 45 (26%) non-
oncological patients, for a total of 53,818 (median 104; range 14e1080) CVC days.
Results: Ninety-four CRBSIs were diagnosed on 238 CVC (infection rate 1.74/1000 CVC days). Coagulase
negative (CoNs) Staphylococci were the most frequently infecting agents (52.8% as single agent) with
17.1% Staphylococcus epidermidis infections. Eighty-three percent S. epidermidis were beta-lattamase
producer (BLACT), 66.6% methicillin-resistant (MR) and 55.5% had a MIC for Vancomicin 1. Gram-
negative bacteria represented 18.6% infections, fungi 7.1%, ﬁnally 15% infections were polymicrobial.
Previous catheterizations and the presence of an enterocutaneous stomawere signiﬁcantly related with a
higher infection risk (p < 0.0001 in both cases).
Conclusions: CRBSI and antibiotic resistance of infecting agents remain an important challenge in adult
patients on HPN; an active research on strategies to counteract the phenomena is required.
© 2016 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.1. Introduction
Parenteral nutrition (PN) is a lifesaving treatment for patients
with chronic benign intestinal failure and an effective support for
patients with gastrointestinal involvement by neoplastic diseases.
Home PN (HPN) is now a well recognized and widely spread pro-
cedure which may be performed in the long-term, thus amelio-
rating patients' quality of life and reducing public health costs [1,2].
Central venous catheter (CVC)-related blood-stream infections
(CRBSI) represent the most serious and common complication of
long-term HPN and can contribute to patients' morbidity andicine and Surgery, Federico II
þ39 (0)81 746 2333.
pia).
for Clinical Nutrition and Metabolmortality; they usually require hospital admission, with increasing
costs for the healthcare system [3e5].
1.1. Aim of the study
The study aims: 1) to retrospectively evaluate CVC infection rate
and the type of infectious agent determining CRBSI in a setting of
oncological and non-oncological outpatients on HPN; 2) to evaluate
possible predictive risk factors of CVC infection and effectiveness of
antibiotic therapy.
2. Patient and methods
A retrospective, observational study on all consecutive patients
receiving HPN from January 2010 to December 2012 at the Clinicalism. All rights reserved.
L. Santarpia et al. / Clinical Nutrition 35 (2016) 1394e1398 1395Medicine and Surgery Department of Federico II University Hos-
pital in Naples, Italy, was performed. Adult patients receiving HPN
for less than 2 weeks and those receiving PN through a peripheral
vein were excluded from the study.
2.1. Patients
Information about age, gender, underlying disease (oncological,
non-oncological), implanted CVC type, number of CRBSI, infecting
agent type, days of catheterization, infusion frequency, previous
CVC infections, duration, modality of antibiotic treatment and
clinical outcome were collected for each patient.
2.2. CRBSI diagnosis
CRBSI diagnosis was made according to the ESPEN and IDSA
guidelines [6,7]. CRBSI is deﬁned as isolation of the same micro-
organism from semi-quantitative or quantitative cultures of both
blood drawn from the catheter lumen and the blood peripherally
drawn of the patient with clinical symptoms of a bloodstream
infection and no other apparent source of infection.
In some circumstances, in particular in terminal oncologic pa-
tients already followed by the oncologist and/or the medical
practitioner, empiric antibiotic therapy was started before taking
blood for culture. In these cases, when no other sources of infection
were suspected, CRBSI diagnosis was performed according to hard
clinical ﬁndings such as fever and shivering during catheter use,
despite the negative/missing blood culture results.
Before HPN initiation, all patients and/or their caregivers
received oral and written instructions by the clinical-nutrition
team on CVC aseptic management and how to recognize both in-
fectious and non-infectious complications [8,9].
2.3. Statistical analysis
The data obtained were analyzed with speciﬁc software for
statistical analysis (SPSS 15.0). Results are expressed as mean,
standard deviation and range. The t-test was used for comparison
of unpaired data and c2 test for proportions. A logistic regression
analyzed the correlation between variables. Multi-variate analysis
was applied for risk factor evaluation. Differences among variables
were considered statistically signiﬁcant for p values <0.05.
3. Results
One hundred seventy two [91 (53%) M, 81 (47%) F] patients
receiving HPN between January 2010 and December 2012 at the
Clinical Nutrition Unit were evaluated.
The study population consisted of 127 (74%) oncological and 45
(26%) non-oncological adult patients, for a total of 53,818 days of
catheterization and 49,254 days of HPN (Table 1). The type of dis-
ease in oncological and non-oncological patients is detailed in
Table 2.
HPN frequency was 7 days per week in 151 (88%) patients, and
3e5 days per week in 21 (12%) patients.
In non-oncological patients, HPN generally began soon after CVC
insertion (1 ± 2 days, min 0, max 10, median 1), whereas in onco-
logical patients CVC generally was previously inserted for intrave-
nous chemotherapy (CHT), even several months before beginning
HPN (71 ± 108 days, 0e639, median 20.5). Twenty-four (14.5%) out
of 172 patients had an enterocutaneous stoma.
A total of 238 CVC were inserted in 172 patients; the type of
catheters inserted was detailed in Table 1. Forty-eight out of 172
(27.9%) patients had already undergone a previous catheterization.Globally, ninety-four CRBSIs were diagnosed on 238 inserted CVC,
corresponding to an infection rate of 1.74/1000 CVC days.
In 70/94 (74.5%) cases blood cultures were positive. In 24/94
(25.5%) cases blood cultures were negative due to the starting of
empiric antibiotic therapy before blood culture.
By focusing the attention only on the 70 infections with positive
blood culture results (Table 3), in 55/70 (78.6%) cases the infection
was due to a single infecting agent and in 15/70 (21.4%) to 2 ormore
germs: 4 with fungi, 9 with 2 infecting agents and 2 with 3 agents,
in these last cases, fungi were always present.
Finally, 83.3% (15/18) isolated S. epidermidis were beta-
lactamase producer, 66.6% (12/18) methicillin resistant and 66.6%
(12/18) had a Minimal Inihibiting Concentration (MIC) for Vanco-
micine 1; 71.4% (5/7) S. aureus infections were methicillin-
resistant (MRSA) with an elevated MIC for vancomicin.
3.1. Clinical outcome
In the 24/94 cases with negative cultures and hard clinical
ﬁndings for CVC infection, the CVCs were promptly removed and
empiric antibiotic therapy started.
As regards the 70 cases with positive blood results, 17 (24.3%)
short-term CVCs were immediately removed; in 20/70 (28.6%)
cases, according the current guidelines [13,14], the catheter was
immediately removed for 9 fungal/polymicrobial infections, 7 S.
aureus and 4 Gram negative (3 Pseudomonas, 1 Klebsiella pneu-
moniae) infections. As far as secondary complications, 3 S. aureus
infections were complicated by septic pneumonia and 1 by septic
endocarditis. Two infections by Gram negative bacteria were
complicated by septic shock; 4 infections were associated with
venous thrombosis.
Systemic and Local Antibiotic Therapy (Antibiotic Lock Therapy)
were performed in the remaining 33/70 (41.14%) cases (Table 4),
and in 22/33 (66.7%) cases the catheter salvage was successful.
Median antibiotic therapy length was 21 (range) 14e28 days
according to the type of infection to treat.
A logistic regression model which considered previous cathe-
terization, CVC use also for chemotherapy, type of catheter and the
presence of a entero-cutaneous stoma as confounding variables,
showed that a previous catheterization was signiﬁcantly related
with a higher infection risk (p < 0.001).
The number of infections per patient was positively related with
days of catheterization (r ¼ 0.57; p < 0.0001) and of HPN (r ¼ 0.61;
p < 0.000), whilst it was not related neither with time lasted be-
tween CVC implant and HPN initiation, nor with the weekly infu-
sion rate.
The infection ratewas higher in patients with a cutaneous stoma
(p ¼ 0.001), with no differences in the type of infecting agents
between patients with or without stoma.
The absolute number of CVC-related bloodstream infections is
signiﬁcantly different (p < 0.0001) but, when corrected for the CVC
infection rate, the difference is not statistically signiﬁcant. Finally,
there were no differences in the type of infecting agents between
oncological and non-oncological patients, as well as, while
considering different types of implanted catheters.
4. Discussion
CRBSI is a severe and frequent complication and a common
cause of hospitalization for adult patients on HPN [3,9]. The infec-
tion rates reported in literature vary from 0.35 to 2.0/1000 days of
catheterization, depending on age and type of patients followed, i.e
oncological or non-oncological, acute or chronic basic disease,
hospitalized or home patients and catheter handling frequency
[3,8e15]. Our nutritional team constantly monitored the
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L. Santarpia et al. / Clinical Nutrition 35 (2016) 1394e13981396phenomena of CRBSI in the time, in particular in adult patients on
HPN, and evaluated possible strategies to reduce the infection rate;
the appropriate CVCmanagement (adequate personnel, patient and
care giver's training) seems a key factor to stem the infection rate in
the time [8,10].
In the past years, uncomplicated CVC-related bloodstream in-
fections due to coagulase-negative staphylococci were successfully
treated in a high (89%) percentage of cases [16,17]. Presently, whilst
the overall infection rate is progressively decreasing in the years, an
increasing and alarming antibiotic resistance has been observed for
all bacteria, particularly for S. epidermidis and CoNs, the most
common infectious agents, with decreased opportunities of CVC
saving [8,10,16,17].
One of the several reasons for antibiotic therapy failure could be
the ability of some bacteria to produce an increased impermeable
bioﬁlm, requiring higher concentrations and prolonged adminis-
tration of antibiotics to defeat the bacteria. The bacteria growing in
the bioﬁlm are in a dormant but viable state and initially may fail to
grow in culture, with false-negative culture ﬁndings; it can
regenerate after the interruption of antibiotic therapy, thus causing
infection relapse [18e21].
For the same reasons, early CRBSI symptoms have changed over
time, thus masking or delaying the diagnosis [22,23]. In the last
years, in fact, thewell-deﬁned CRBSI symptoms (shivering followed
by high temperature, strictly associated with parenteral nutrition
infusion) have become less frequent at the onset of infection,
whereas in 57.6% cases, non-speciﬁc symptoms such as prolonged
mild fever in the absence of shivering, osteo-articular pain and
headache (not strictly related to nutrition infusion time) have been
observed. Despite a lack of observation in literature regarding the
fading of CVC infection symptoms, Machado et al. reported evi-
dence of catheter tip infection in spite of the absence of clinical
symptoms in 50% of CVC used for Parenteral Nutrition and removed
after therapy termination according to prescription [24]. Our study
conﬁrms a higher risk of infection in patients who have undergone
a previous catheterization [25].
Our work presents a rate of isolated germs equivalent to 74.5%; a
non-optimal result. The reason lies in the fact that most patients of
this study are oncological and among them, some are terminal and
home bedridden. In presence of fever, often an empirical antibiotic
therapy was started before culture sampling, under the supervision
of the oncologist or their general practitioner. In these cases,
despite the negative/missing blood culture, the diagnosis of CRBSI
was performed according to extremely signiﬁcant clinical ﬁndings.
The most frequently used antibiotics for empiric therapy were
Piperacillin/Tazobactam and Ceftriaxone.
Antibiotic therapeutic efﬁcacy, high in the ﬁrst years of our
clinical activity [8], gradually reduced in time, due to increasing
microbial antibiotic-resistance. In fact, in our experience, the rate of
successful antibiotic therapy for S. epidermidis CVC infections
dropped from a value higher than 80% in 1995 to less than 40% in
2006 [10]. In this study, antibiotic therapy succeeded in 66.6% cases,
in our opinion, also thanks to the use of Daptomicin, when
appropriate. According to the literature, in case of MR bacteria with
an MIC for vancomicin >2 mg/mL, Daptomicin is indicated [26,27].
This antibiotic has a potent in-vitro effect against bioﬁlms, and
numerous studies have shown its effectiveness in the treatment of
CVC infections by coagulase negative staphylococci or Enterococcus
faecalis, especially when combined with Rifampicin due to their
synergistic action on the bacterial bioﬁlm [26,28,29]. In our expe-
rience, Daptomicin proved its effectiveness by sterilizing all treated
catheters.
In our study, the infection rate and the probability of CVC saving
were not affected by the type of implanted CVC (totally implant-
able, tunneled, short term) whilst methicillin resistance or the
Table 2
Primary diseases in the 127 oncological and 145 non-oncological patients evaluated since January 2010 to December 2012.
n. Type of disease n. Primary disease Indication for HPN
45 Non-oncological
29 Short bowel syndrome 9 Mesenteric infarction Intestinal malabsorption
7 Multiple intestinal resections (Crohn)
4 Radiation enteritis
5 Postsurgical adhesions
4 Intestinal volvulus
16 Other diseases 4 Systemic sclerosis and other collagen diseases
4 Bariatric surgery complications
4 Active Crohn's disease
2 Eosinophilic enteropathy
2 Intestinal pseudo-obstruction Intestinal dismotility
127 Oncological
127 Peritoneal carcinomatosis 52 Gastro-esophageal cancer Intestinal sub-obstruction/obstruction
18 Pancreas or biliary tract cancer
43 Colon cancer
8 Ovarian or uterine cancer
6 Advanced cancer of other origins
Table 3
Infecting agents of the 70 positive cultures in 172 patients followed up since January
2010 to December 2012.
Number of checks Single agent Associated
Gram positive bacteria 55/70 (78.6%) 37 18
S. epidermidis 18/70 (25.7%) 12 6
CoNs Staphylococci 24/70 (34.3%) 17 8
S. aureus 7/70 (10%) 6 1
Enterococcus 3/70 (4.3%) 2 1
Streptococcus 2/70 (2.8%) e 1
Corynebacteria 1/70 (1.4%) e 1
Gram negative bacteria 21/70 (30%) 13 8
Klebsiella spp. 8/70 (11.4%) 4 4
Enterobacteria 6/70 (8.6%) 5 1
E. coli 3/70 (4.3%) 1 2
Pseudomonas spp. 3/70 (4.3%) 3 e
Proteus spp. 1/70 (1.43%) e 1
Fungi 9/70 (12.8%) 5 4
C. albicans 5 (5.3%) 3 2
C. glabrata 4 (4.3%) 2 2
Polimicrobial infections 15/70 (21.42%) e e
CoNs ¼ Coagulase negative Staphylococci.
Table 4
Systemic and local antibiotic therapy in the 33 treated cases.
Treated cases, n (%) Lock therapy Systemic therapy
11 Teicoplanin Carbapenems (Meropenem, Imipenem),
6 Teicoplanin Quinolons (Ciproﬂoxacin/Levoﬂoxacin)
3 Teicoplanin Aminoglycosides (Gentamicin/Netilmicin)
9 Daptomicin Rifampicin
4 Meropenem Ciproﬂoxacin
L. Santarpia et al. / Clinical Nutrition 35 (2016) 1394e1398 1397presence of bacteria with an MIC for Vancomicin 1 strongly
increased the probability of CVC removal.
To counteract the winning and reﬁned mechanisms of antibiotic
resistance, prevention with a strict compliance to evidence-based
instructions for correct CVC management seems the only real
effective strategy against CRBSI, in particular in patients receiving
long term HPN, with the needing of strict a clinical supervision by a
well trained team and adherence to evidence-based instructions for
CVC management [8,10].
Taurolidine lock has recently been shown to be beneﬁcial as
secondary prophylaxis for patients with recurrent episodes of
CRBSI and as primary prophylaxis in selected patients, such as for
those with very limited vascular access [30e32]. Further multi-
center randomized studies are required to better deﬁne which
patients could beneﬁt from taurolidine lock.Funding source
None.Conﬂict of interest
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